Abstract:Buoyed by the discovery of small-molecule tyrosine kinase inhibitors (smTKI), significant impact has been made in cancer chemotherapeutics. However, off-target toxicities and suboptimal efficacies are still encountered with some of these agents due to their inferior biopharmaceutical and/or pharmacokinetic properties. Almost all of these molecules exhibit significant inter- and intra-patient differences in plasma concentration-time profiles. Thus, therapeutic drug monitoring, dose adjustments and precision medicine are being contemplated by clinicians. Complex formulations or nanoformulation-based drug delivery systems offer a promising approach in providing drug encapsulation or spatiotemporal control over the release to overcome the biopharmaceutical and pharmacokinetic limitations and improve the therapeutic outcomes. In this context, the present review comprehensively tabulates and critically analyses all the relevant properties (T 1/2 , solubility, pK a , therapeutic index, IC 50 , metabolism etc.) of the approved smTKIs, which should enable an informed selection of a drug amongst this class of therapeutics for development into complex formulations. Detailed appraisal of the advances made in complex formulations of smTKIs, focusing on strategies to enhance their pharmacokinetic profile, tumor targeting ability, and therapeutic efficacy. Various nanocarrier platforms, including micelles, polymeric nanoparticles, liposomes, nanosponges, nanocrystals, nanocapsules, and carbon nanotubes (CNTs), have been discussed, highlighting their unique features and potential applications in cancer therapy. Nanoformulations have been shown to improve area under the curve and peak plasma concentration and reduce dosing frequency for several smTKIs in animal models. It is inferred that extensive efforts will be made in complex formulations of smTKIs in near future thus, the paper concludes with key recommendations for developing complex formulations of smTKI so that early clinical translation is realized. Graphical Download: Download high-res image (242KB) Download: Download full-size image

Nanoformulations of small molecule protein tyrosine kinases inhibitors potentiate targeted cancer therapy

Advances in Small-Molecule Inhibitors of Protein Tyrosine Kinases

Biopharmaceutical and pharmacokinetic attributes to drive nanoformulations of small molecule tyrosine kinase inhibitors

Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective

Advances in studies of tyrosine kinase inhibitors and their acquired resistance

Emerging Roles of Targeted Small Molecule Protein-Tyrosine Kinase Inhibitors in Cancer Therapy

Nanotechnology in the development of small and large molecule tyrosine kinase inhibitors and immunotherapy for the treatment of HER2-positive breast cancer

The Progress of Tyrosine kinase Inhibitors in Cancer Therapy

Review on the Research Development of Small Molecular Protein Tyrosine Kinases Inhibitors

Kinase Inhibitors and Kinase-Targeted Cancer Therapies: Recent Advances and Future Perspectives

Solid Lipid Nanoparticles for Efficient Oral Delivery of Tyrosine Kinase Inhibitors: A Nano Targeted Cancer Drug Delivery

Protein-Based Artificial Nanosystems in Cancer Therapy

Advances in Nanotechnology-Based Delivery Systems for EGFR Tyrosine Kinases Inhibitors in Cancer Therapy

Advances in the Research of Small Molecule Tyrosine Kinase Inhibitors

Kinase-targeted cancer therapies: progress, challenges and future directions

Insights into Lipid-Based Delivery Nanosystems of Protein-Tyrosine Kinase Inhibitors for Cancer Therapy

Protein Kinases as Tumor Biomarkers and Therapeutic Targets

Targeting oncogenic kinases: Insights on FDA approved tyrosine kinase inhibitors

Targeting PTPs with small molecule inhibitors in cancer treatment

Recent Advances in the Discovery of Multitargeted Tyrosine Kinase Inhibitors As Anticancer Agents

Small molecules in targeted cancer therapy: advances, challenges, and future perspectives